



# **Electronic Publication of Patents Journal under The Patents (Amendments) Act, 2016**

Weekending:- 15-07-2016

Legal Publication Date:- 26-07-2016

Journal Code (160726)

## NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

<b>11-07-2016</b>		
412/2016	RKW SE Germany (Priority 02-09-2011 EP) <b>Divisional</b>	“Process for stretching a film Web”
<b>12-07-2016</b>		
413/2016	Institute of Space Technology Islamabad - Pakistan	“Biomedical imaging system for direct detection of peripheral vascular disorders and cancer diseases using deep depletion charge coupled device (DDCCD)
414/2016	Powerhands Inc USA (Priority 30-12-2014 US)	“Sports Training Ball Assembly”
415/2016	F. Hoffmann-LA Roche AG Switzerland (Priority 14-07-2015 EP)	“Imidazole derivatives”
416/2016	H. Lundbeck A/S Denmark (Priority 13-07-2015 UK)	“Agents, Uses and methods for the treatment”
417/2016	H. Lundbeck A/S Denmark (Priority 13-07-2015 UK)	“Agents, Uses and methods for the treatment of synucleinopathy”

418/2016	H. Lundbeck A/S Denmark (Priority 13-07-2015 UK)	“Antibodies specific for hyperphosphorylated tau and methods of use thereof”
419/2016	E I DU P[ONT DE NEMOURS AND COMPANY USA (Priority 13-07-2015 US)	“Aryloxypyrimidinyl ethers as herbicides”
420/2016	ELI LILLY AND COMPANY USA (Priority 27-07-2015 EP)	“Mutant IDHI Inhibitors”
<b>13-07-2016</b>		
421/2016	Atta ul Wasay Mohsin Islam Tiwana Javed Iqbal Nasir Rasheed <b>NUST</b> – Islamabad – Pakistan	“Torque adjustable coupling for Hand prosthesis”
422/2016	Atta ul Wasay Mohsin Islam Tiwana Javed Iqbal Nasir Rasheed <b>NUST</b> – Islamabad – Pakistan	“Under actuated Uni-Motor Device Mechanism for adaptive grasp upper limb”
423/2016	Pfizer Inc USA (Priority 15-07-20515 US)	“Pyrimidine Derivatives”

424/2016	Starling & Co. Gesellschaft m.b.H Austria (Priority 20-07-2015 EP)	“Weaving shuttle”
425/2016	F. Hoffmann-LA Roche AG Switzerland (Priority 15-03-2015 EP)	“Ethynyl Derivatives”
<b>14-07-2016</b>		
426/2016	Stoller Enterprises, Inc USA (Priority 14-07-2015 US)	”A HIGH CONCENTRATION LOW VOC LIQUID GIBBERELLIN”
427/2016	Hussain Ahmad Peshawar – Pakistan	“Development of a prototype for the Generation of Hydrogen from Organic wastes in high yield”
428/2016	Honda Motor Co., Ltd Japan (Priority 23-07-2016 TH)	“Instrument panel structure”
429/2016	AbbVie s.a.r.l Belgium (Priority 16-07-2015 US)	“Substituted Tricyclics and Method of use”
<b>15-07-2015</b>		
430/2016	Afzaal Mustafa Islamabad – Pakistan	“Multipurpose Hanging Rod System”

431/2016	Bayer Pharma Aktiengesellschaft Germany (Priority 27-07-2015 EP)	“METHOD FOR PREPARING SUBSTITUTED 3-(ANILINO-1-CYCLOHEXYL-1H- BENZIMIDAZOL-5-YL) PROPANOIC ACID DERIVATIVES”
432/2016	Bayer Pharma Aktiengesellschaft Germany (Priority 27-07-2015 EP)	“INHIBITOR OF THE MUTATED ISOCITRATE DEHYDROGENASE IDHI R-132H”
433/2016	Monsanto Technology LLC USA (Priority 22-07-2015 US)	“Methods and compositions for selective regulation of protein expression .
434/2016	Takeda Pharmaceutical Company Japan (Priority 17-07-2015 JP)	“Heterocyclic Compounds”
435/2016	AXOVANT SCIENCES LIMITED Bermuda (Priority 15-07-2015 US)	“DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5- HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF HALLUCINATIONS ASSOCIATED WITH A NEURODEGENERATIVE DISEASE”



## APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.


The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

106/2010	DOW AGROSCIENCES LLC. U.S.A.	<p>"Compound of (3R,4R,5S,6S)-2,3,4,5-tetramethoxy-6-methyl-tetrahydropyran"</p> <p>C07H15/26 and A01N43/16.</p> <p style="text-align: right;"><b>142380</b></p> <p>The invention disclosed in this document is related to the field of pesticides. A compound having the following structure is disclosed.</p> <div style="text-align: center;"><p>where</p></div> <p>is referred to as Ar2 wherein:</p> <p>(a) Ar is</p> <p>(1) furanyl, phenyl, pyridazinyl, pyridyl, pyrimidinyl, thiadiazolyl, thienyl, or</p> <p>(2) substituted furanyl, substituted phenyl,</p>
----------	------------------------------------	---

		<p>substituted pyridazinyl, substituted pyridyl, substituted pyrimidinyl, substituted thiadiazolyl, or substituted thienyl, Het, R1, R2, R3, R4, m, Ra and Rb as defined in claims, and their use in controlling pests.</p>
861/2011	DOW AGROSCIENCES LLC. U.S.A.	<p>"PROCESSES FOR THE PREPARATION OF ENAMINE"</p> <p>C0D7295/084 and A01N43/42.</p> <p style="text-align: right;"><b>142381</b></p> <p>The invention disclosed in this document is related to the field of process for the preparation of an enamine said process comprising:</p> <p>(A) reacting, in a reaction zone that comprises a solvent, an amine and a carbonyl to produce an enamine and H<sub>2</sub>O</p> $  \begin{array}{c} \text{R1} \\   \\ \text{R2}-\text{C}-\text{C} \\   \quad \backslash \\ \text{H} \quad \text{O} \end{array} + \begin{array}{c} \text{H} \\   \\ \text{R4}-\text{N}-\text{R5} \end{array} \longrightarrow \begin{array}{c} \text{R1} \quad \text{R3} \\ \backslash \quad / \\ \text{C}=\text{C} \\ / \quad \backslash \\ \text{R2} \quad \text{N} \\ \quad \quad \backslash \\ \quad \quad \quad \text{R4} \\ \quad \quad \quad \quad \backslash \\ \quad \quad \quad \quad \quad \text{R5} \end{array} + \text{H}-\text{O}-\text{H}  $ <p>(1) wherein said amine has the following formula</p> $  \begin{array}{c} \text{H} \\   \\ \text{R4}-\text{N}-\text{R5} \end{array}  $ <p>wherein R4 and R5 are each independently selected from C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>2</sub>-C<sub>8</sub> alkoxyalkyl, C<sub>7</sub>-C<sub>12</sub> arylalkyl, C<sub>2</sub>-C<sub>8</sub> alkylaminoalkyl, aryl, and heteroaryl, or R4 and R5 taken together with N represent a 5- or 6-membered</p>

saturated or unsaturated ring; and  
(2) wherein said carbonyl (i.e. an aldehyde or a ketone) has the following formula



(a) wherein R1 and R2 is each independently selected from C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>2</sub>-C<sub>8</sub> alkoxyalkyl, C<sub>7</sub>-C<sub>12</sub> arylalkyl, C<sub>2</sub>-C<sub>8</sub> alkylaminoalkyl, aryl, and heteroaryl, each of which is independently substituted with one or more S-R6 wherein each R6 is independently selected from C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>2</sub>-C<sub>8</sub> alkoxyalkyl, C<sub>7</sub>-C<sub>12</sub> arylalkyl, C<sub>2</sub>-C<sub>8</sub> alkylaminoalkyl, aryl, and heteroaryl, and

(b) wherein R3 is selected from H, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>2</sub>-C<sub>8</sub> alkoxyalkyl, C<sub>7</sub>-C<sub>12</sub> arylalkyl, C<sub>2</sub>-C<sub>8</sub> alkylaminoalkyl, aryl, and heteroaryl; or said carbonyl is 3-methylsulfanylbutyraldehyde;

(3) wherein said reacting, in said reaction zone, is conducted under distillation conditions comprising

(a) a pressure from about 100 Pascals (Pa) to about 120,000 Pa, and

(b) a temperature below about, but preferably below, the thermal decomposition temperature of said enamine during said reacting; and

(4) wherein said solvent initially comprises a non-polar-high-boiling-point liquid, a polar-high-boiling-point-liquid,



		<p>and then further comprises H<sub>2</sub>O produced from the condensation of said amine and said carbonyl to produce said enamine; and</p> <p>(B) removing a vapor phase from said reaction zone wherein said vapor phase comprises H<sub>2</sub>O.</p>
938/2011	INNOVATION & RESEARCH S.R.L., Italy.	<p>"Machine and its process for dyeing of reels of yarn and/or textile fibres wound on packages"</p> <p>D06B5/16.</p> <p style="text-align: right;"><b>142382</b></p> <p>This invention relates to a machine (1) for the dyeing of reels of yarn (8) and of textile fibres wound on packages. The machine (1) comprises: a structure (2) that delimits a chamber (3) at least partially or fully filled with at least a dyeing fluid (4); support means (6), in particular at least one support plate (6), immersed in the dyeing fluid (4); a plurality of reel-holder rods (7) that communicate via the fluid with the support means (6) to allow the dyeing fluid (4) to pass between the latter; recirculation means (9) for the dyeing fluid (4) associated with the structure (2) to initiate the transit of the dyeing fluid (4) in accordance with at least one set route. The recirculation means (9) comprise an initial recirculation mechanism (10) interposed between the chamber (3) and the support plate (6) to induce the dyeing fluid (4) to pass through the reel-holder rods (7). The</p>

first recirculation mechanism (10) comprises a pump (10a) and respective selection mechanisms (12) to channel the dyeing fluid through the support means (6), the reel- holder rods (7) and the respective reels (8), on an intermittent basis. The recirculation means (9) comprise a second recirculation mechanism (11), to induce the transit of the dyeing fluid (4) within the chamber (3) in accordance with at least one closed route.






Figure-1


93/2012	POLICHEM SA. Luxembourg.	<p>"A PHARMACEUTICAL COMPOSITION COMPRISING NIFURATEL TO TREAT INFECTIONS CAUSED BY Clostridium SPECIES"</p> <p>A61K31/422 and A61P31/04.</p>
---------	-----------------------------	---



		<p style="text-align: right;"><b>142383</b></p> <p>The present invention is directed to a pharmaceutical composition comprising nifuratel, or a physiologically acceptable salt thereof, to treat infections caused by bacteria species of the genus Clostridium. The invention is further directed to a pharmaceutical composition of nifuratel to treat Clostridium difficile infection (CDI) and in particular Clostridium difficile associated diarrhoea (CDAD).</p>
822/2012	CHIESI FARMACEUTICI S.p.A., Italy.	<p>"A compound of 1 -(5-tert-Butyl-2-(4-methoxy-phenyl)-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-isopropyl-[1,2,4]triazolo[4,3-a] pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl] -urea"</p> <p>A61K31/5377 and C07D471/04.</p> <p style="text-align: right;"><b>142384</b></p> <p>Compound of formula (I):</p> <div style="text-align: center;">  <p style="text-align: right;">(I)</p> </div> <p>wherein R<sup>2</sup>, W,A,Y and R<sup>1</sup> are as defined in the specification, are p38 MAPK inhibitor, useful as anti-inflammatory agent in the treatment of, <i>inter alia</i>, diseases of the respiratory tract.</p>

854/2012	Akzo Nobel Coatings International B.V. The Netherlands.	<p>"DRIER FOR AUTO-OXIDISABLE COATING COMPOSITIONS"</p> <p>C09D167/06,C09D7/04,C09D7/12, C08K3/10,C08K13/02,C08K5/3467 and C08K5/00.</p> <p style="text-align: right;"><b>142385</b></p> <p>A mixture for use as a drier for air-drying an auto-oxidizable resin composition, said mixture comprising: 1,4,7-trialkyl- 1,4,7-triazacyclononane (L); and, a manganese salt having the general formula <math>Mn^{2+}[X]_n</math>, wherein anion X is selected from <math>PF_6^-</math>, <math>SbF_6^-</math>, <math>AsF_6^-</math>, <math>BF_4^-</math>, <math>B(C_6F_5)_4^-</math>, <math>Cl^-</math>, <math>Br^-</math>, <math>I^-</math>, <math>NO_3^-</math>, or <math>R_2COO^-</math> in which case <math>n=2</math>, or the anion X is <math>SO_4^{2-}</math> in which case <math>n=1</math>, and wherein <math>R_2</math> is <math>C_1</math>-<math>C_{20}</math> alkyl optionally substituted with heteroatoms, <math>C_6</math>-<math>C_{20}</math> aryl optionally substituted with heteroatoms, or a polymeric residue; wherein the 1,4,7-trialkyl-1,4,7-triazacyclononane (L) is present in the mixture in an amount such that the molar ratio of L:Mn is at least 1.25:1 and more preferably at least 1.5:1.</p>
855/2012	Akzo Nobel Coatings International B.V. The Netherlands.	<p>" DRIER FOR AUTO-OXIDISABLE COATING COMPOSITIONS"</p> <p>C09D167/06,C09D7/04,C09D7/12,C08K3 /10,C08K5/00,C08K13/02 and C08K5/3467.</p> <p style="text-align: right;"><b>142386</b></p> <p>A drier for air-drying an auto-oxidizable resin composition, said drier comprising:</p>


		<p>1,4,7-trialkyl-1,4,7-triazacyclononane (L); a manganese salt having the general formula <math>Mn^{2+}[X]_n</math>, wherein anion X is selected from <math>PF_6^-</math>, <math>SbF_6^-</math>, <math>AsF_6^-</math>, <math>BF_4^-</math>, <math>B(C_6F_5)_4^-</math>, <math>Cl^-</math>, <math>Br^-</math>, <math>I^-</math>, <math>NO_3^-</math>, or <math>R_2COO^-</math> in which case <math>n=2</math>, or the anion X is <math>SO_4^{2-}</math> in which case <math>n=1</math>, and wherein <math>R_2</math> is <math>C_1</math>-<math>C_{20}</math> alkyl optionally substituted with heteroatoms, <math>C_6</math>-<math>C_{20}</math> aryl optionally substituted with heteroatoms, or a polymeric residue; wherein the 1,4,7-trialkyl-1,4,7-triazacyclononane (L) is present in the mixture in an amount such that the molar ratio of Mn:L is at least 1.25:1 and preferably at least 1.5:1.</p>
44/2013	Novartis AG. Switzerland.	<p>"A PRE-FILLED SYRINGE"</p> <p>A61F9/0008,A61K9/0019 and A61M5/178.</p> <p style="text-align: right;"><b>142387</b></p> <p>The Present invention relates to a pre-filled syringe comprising a glass body, a stopper and a plunger. The body of syringe comprising an outlet at an outlet end and the stopper being arranged within the body such that a front surface of the stopper and the body define a variable volume chamber from which a fluid can be expelled through the outlet, the plunger comprising a plunger contact surface at a first end and a rod extending between the plunger contact surface and a rear portion, the plunger contact surface arranged to contact the stopper, such that the plunger</p>

		<p>can be used to force the stopper towards the outlet end of the body, reducing the volume of the variable volume chamber, characterised in that the fluid comprises an ophthalmic solution.</p> <p>The syringe of present invention is suitable for ophthalmic injections, more particularly intravitreal injections and as such has a suitably small volume syringe. The syringe may also be silicone oil free, or substantially silicone oil free, or may comprise a low level of silicone oil as lubricant and despite the low silicone oil level, the stopper break loose and slide force is less than 20N.</p>  <p style="text-align: center;">Fig 1</p>
348/2013	DOW AGROSCIENCES LLC. U.S.A.	<p>"Process to produce certain 2-(pyridine-3-yl)thiazol-5-amine as intermediate for the synthesis of pesticidal 2-(pyridine-3-yl)thiazol-5-yl amide"</p> <p>C07D417/04 and A01N43/78.</p> <p style="text-align: right;"><b>142388</b></p> <p>The invention disclosed in this document is related to the field of process to produce certain 2-(pyridine-3-yl)thiazol-5-amine as intermediate for the synthesis of pesticidal 2-(pyridine-3-yl)thiazol-5-yl amide. The process comprises reacting compound (I) with compound (IIa) to produce compound (IIb); followed by reacting</p>


		<p>compound (IIb) with compound (IIc) to produce compound (III); followed by cyclizing compound (III) using a dehydrating agent to produce compound (IV); and optionally, further comprises halogenating compound (IV) at R<sup>3</sup>.</p> 
762/2013	Stora Enso OYJ. Finland. Wetend Technologies Ltd. Finland.	<p>"IN-LINE PRODUCTION METHOD FOR PAPER MAKING PROCESS"</p> <p>D21H17/70, D21H11/18 and D21H17/25.</p> <p><b>142389</b></p> <p>The present invention relates to an in-line production method for providing a liquid flow of at least one additive in the short circulation and into the liquid flow of a paper making stock of a fiber web machine by feeding, the liquid flow of the at least one additive to the liquid flow of the short circulation, wherein a suitable amount of a microfibrillated cellulose or nanofibrillated polysaccharide is provided substantially simultaneously with the feeding of liquid flow of the at least one additive</p>

		
08/2014	<p>1) Savira pharmaceuticals GmbH; Austria.</p> <p>2) European Molecular Biology Laboratory. Germany.</p> <p>3) F. Hoffmann-La Roche AG. Switzerland.</p>	<p>"9-Hydroxy-3,4-dihydro-2H-pyrazino[1,2c]pyrimidine-1,8-dione compound"</p> <p>A61K31/519, A61P31/12 and C07D487/04.</p> <p style="text-align: right;"><b>142390</b></p> <p>The present invention relates to a compound having the general formula (I),</p> <div style="text-align: center;">  <p>(I)</p> </div> <p>wherein</p> <p><b>R<sup>10</sup></b> is -H, a -C<sub>1-6</sub> alkyl group or a -C(O)-C<sub>1-6</sub> alkyl group;</p> <p><b>R<sup>11</sup></b> is -H, a -C<sub>1-6</sub> alkyl group, or a -C<sub>1-6</sub> alkyl group which is substituted by one or more halogen atoms;</p> <p><b>R<sup>12</sup></b> is -H, a -C<sub>1-6</sub> alkyl group, or a -C<sub>1-6</sub> alkyl group which is substituted by one or more halogen atoms;</p>




		<p>or wherein <math>R^{11}</math> and <math>R^{12}</math> can be joined together to form a 3- to 7-membered carbo or heterocyclic ring;  <math>R^{13}</math> is <math>-R^{16}</math>, or <math>-X^{10}-R^{16}</math>;  <math>R^{14}</math> is <math>-H</math>, <math>-(\text{optionally substituted } C_{1-6} \text{ alkyl})</math>, <math>-(\text{optionally substituted } C_{3-7} \text{ cycloalkyl})</math>, <math>-(\text{optionally substituted aryl})</math>, <math>-C_{1-4} \text{ alkyl}-(\text{optionally substituted } C_{3-7} \text{ cycloalkyl})</math>, or <math>-C_{1-4} \text{ alkyl}-(\text{optionally substituted aryl})</math>;  <math>R^*</math> is independently selected from <math>-H</math>, <math>-C_{1-6} \text{ alkyl}</math>, and <math>-C_{3-7} \text{ cycloalkyl}</math>.</p>
454/2014	CHIESI FARMACEUTICI S.p.A., Italy.	<p>"IMPROVED PROCESS FOR THE PREPARATION OF DERIVATIVES OF 1-(2-FLUORO[1,1'-BIPHENYL]-4-YL)-CYCLOPROPANECARBOXYLIC ACID"</p> <p>C07C253/30 and C07C67/30.</p> <p style="text-align: right;"><b>142391</b></p> <p>The present invention relates to a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof:</p> <div style="text-align: center;">  <p>(I)</p> </div> <p>wherein R represents one or more groups independently selected from</p>

fluorine, chlorine, bromine, and iodine, said process comprising the cyclopropanation of a compound of formula (II) with ethylene carbonate or ethylene sulfate:



(II)

wherein X is chlorine, bromine, iodine or a triflate group (CF<sub>3</sub>SO<sub>3</sub>) or a



group wherein R is as defined above and G is -CN or —COOR<sub>2</sub> wherein R<sub>2</sub> is a C1-C4 straight or branched alkyl chain.

**CORRIGENDUM**

In the Gazette of Pakistan Part-V issued dated **18-04-2016**, under the Heading “**NEW APPLICATION FOR THE PATENTS**”. The following correction are as under :-

**NEW APPLICATION FOR THE PATENTS**

(Correction in Applicant Name Spelling against Patent Application No. **192/2016** only)

**Applicant Name**

**For : Neelum Munir**

**Read : Neelma Munir**

**CORRIGENDUM**

In the Gazette of Pakistan Part-V issued dated **17-06-2016**, under the Heading “**NEW APPLICATION FOR THE PATENTS**”. The following correction are as under :-

**NEW APPLICATION FOR THE PATENTS**

(Correction in Title against Patent Application No. **333/2016** only)

**Title**

**For : Existing entries**

**Read : “METHODS AND COMPOSITIONS FOR REDUCING DIGESTIVE/ABSORPTIVE RATES AND RATIO OF FOOD/DRINKS OR REDUCING A DIGESTIVE SOLUTION”**

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) SECTION 37**  
**(b) OF THE PATENTS ORDINANCE 2000**

In the matter of Patent No. 141441 of 22/8/2007, (Priority date: 22/8/2006 India), Granted to: - **Ranbaxy Laboratories Limited**, an Indian Corporation, of Plot No. 90, Sector 32, Gurgaon 122001, Haryana, India.

In pursuance of an application received on 29/03/2016.

The following entry has been made in the Register of Patents:-

**Sun Pharmaceutical Industries Limited**, (a company incorporated under the companies Act. 1956), of Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai, Maharashtra 400 063, India, as proprietor by virtue merger made between **Ranbaxy Laboratories Limited** was merged into **Sun Pharmaceutical Industries Limited** w.e.f 9<sup>th</sup> March, 2015 according by the merger certificate.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) SECTION 37**  
**(b) OF THE PATENTS ORDINANCE 2000**

In the matter of Patent No. 141446 of 20/09/2010, Ante Date: 22/8/2007, (Priority date: 22/8/2006 India), Granted to: - **Ranbaxy Laboratories Limited**, an Indian Corporation, of Plot No. 90, Sector 32, Gurgaon 122001, Haryana, India.

In pursuance of an application received on 29/03/2016.

The following entry has been made in the Register of Patents:-

**Sun Pharmaceutical Industries Limited**, (a company incorporated under the companies Act. 1956), of Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai, Maharashtra 400 063, India, as proprietor by virtue merger made between **Ranbaxy Laboratories Limited** was merged into **Sun Pharmaceutical Industries Limited** w.e.f 9<sup>th</sup> March, 2015 according by the merger certificate.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) SECTION 37**  
**(b) OF THE PATENTS ORDINANCE 2000**

In the matter of Patent No. 137188 of 02/12/1999, Granted to: - **Ranbaxy Laboratories Limited, a corporation under the laws of India, of 19 Nehru Place, New Delhi 110 019, India.**

In pursuance of an application received on 29/03/2016.

The following entry has been made in the Register of Patents:-

**Sun Pharmaceutical Industries Limited**, (a company incorporated under the companies Act. 1956), of Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai, Maharashtra 400 063, India, as proprietor by virtue merger made between **Ranbaxy Laboratories Limited** was merged into **Sun Pharmaceutical Industries Limited** w.e.f 9<sup>th</sup> March, 2015 according by the merger certificate.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(1) SECTION 37**  
**(a) OF THE PATENTS ORDINANCE 2000**

In the matter of Patent No. **138330** of 10/12/2002 (Priority date 11/12/2001 Germany) Granted to:- **Bayer Aktiengesellschaft**, of D-51368 Leverkusen, Federal Republic of Germany, a body corporate organized under the laws of the Federal Republic of Germany.

In pursuance of an application received on 03/04/2015.

The following entry has been made in the Register of Patents:-

**BAYER INTELLECTUAL PROPERTY GMBH**, a company organized and existing under the laws of Germany, Alfred-Nobel-Strasse 10, 40789 Monheim am Rhein, Germany. as proprietor by virtue of Deed of Assignment dated 10<sup>th</sup> February, 2015 made between, **Bayer Aktiengesellschaft**, as Assignor of the one part and, **BAYER INTELLECTUAL PROPERTY GMBH** as Assignee of the other parts.



**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) SECTION 37**  
**(b) OF THE PATENTS ORDINANCE 2000**

In the matter of Patent No. **141698** of **04/5/2007** Priority date **05/5/2006** (USA). Accepted in the name of: - **IRM LLC** (a Delaware Limited Liability Company), of Hurst Holme, 12 Trott Road Hamilton, Bermuda, HM 11.

In pursuance of an application received on 28/01/2016.

The following entry has been made in the Register of Patents:-

**Novartis International Pharmaceutical Ltd**, a company organized and existing under the laws of Bermuda, 131 Front Street, Hamilton HM 12, Bermuda, As proprietor by virtue of merger of **IRM LLC and merged into Novartis International Pharmaceutical Ltd**, according to the deed of merger dated 5<sup>th</sup> January, 2015.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) SECTION 37**  
**(b) OF THE PATENTS ORDINANCE 2000**

In the matter of Patent No. **141698** of **04/5/2007** Priority date **05/5/2006** (USA). Accepted in the name of: - **IRM LLC** (a Delaware Limited Liability Company), of Hurst Holme, 12 Trott Road Hamilton, Bermuda, HM 11, **and** later on merged into **Novartis International Pharmaceutical Ltd.**

In pursuance of an application received on 28/01/2016.

The following entry has been made in the Register of Patents:-

**NOVARTIS AG**, a company organized and existing under the laws of Switzerland, Lichstrasse 35, 4056 Basel, Switzerland, as proprietor by virtue of deed of assignment dated 26<sup>th</sup> November, 2015 made between **Novartis International Pharmaceutical Ltd.**, as Assignor of the One Part and **NOVARTIS AG**, as assignee of the Other Part.

## **NOTIFICATION**

### **PROCEEDING UNDER SECTION 42 OF PATENT ORDINANCE, 2000**

Any person may give notice of opposition to the amendment proposed in the under mentioned patent No. 141993 dated 18/10/2011, lodging Form 7 of the Patent Rules, 2003 together with the prescribed fee of Rs. 1500/- at any time within two months from the date of advertisement in the Gazette, at the Patent Office, 2<sup>nd</sup> Floor Kandawala Building, M.A. Jinnah Road, Karachi.

**NOVARTIS AG (a Swiss corporation), of Lichtstrasse 35, 4056 Basel, Switzerland.**

SEEK TO AMEND THE Specification Page 179 IN CLAIM 9 as above for the invention entitled:

**“SUBSTITUTED 7,8-DIHYDROPYRIDO[2,3-b]PYRAZINYL/PYRIDINYL  
COMPOUND”.**

The proposed amendment is desired by way of correction.

The proposed amendment may be inspected in the Patent Office.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) SECTION 37**  
**(b) OF THE PATENTS ORDINANCE 2000**

In the matter of Patent No. **142316** of **25/03/2014** Priority date **27/03/2013** (Europe). Accepted in the name of: - **UREA CASALE SA**, a Swiss company, of Via Giulio Pocobelli, 6, CH-6900 Lugano-Besso, Switzerland.

In pursuance of an application received on 13/05/2016.

The following entry has been made in the Register of Patents:-

**CASALE SA**, of Via Pocobelli 6, CH-6900 Lugano, Switzerland, As proprietor by virtue of merger of **UREA CASALE SA** merged into **CASALE SA** w.e.f **24<sup>th</sup> April, 2014** as per merger agreement.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) SECTION 37**  
**(b) OF THE PATENTS ORDINANCE 2000**

In the matter of Patent No. 138602 of 14/10/2003 Priority date 15/10/2002 (GB). Granted to: - **Wyeth**, a corporation organised and existing under the laws of the State of Delaware, United States of America, of Five Giralda Farms, Midison, new Jersey 07940, United States of America, **and** later on whose name was changed to **Wyeth LLC**, and again assigned to **ZOETIS W LLC** (formerly known as PAH W LLC)OF 100 Campus Drive, Florham Park, New Jersey 07932, United States of America.

In pursuance of an application received on 27/7/2015.

The following entry has been made in the Register of Patents:-

**ZOETIS SERVICES LLC, of 100 Campus Drive, Florham Park, NJ 07932, United States of America.**, as proprietor by virtue of Merger of **ZOETIS W LLC** into **ZOETIS SERVICES LLC** as per merger certificate dated 26<sup>th</sup> April, 2015.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) SECTION 37**  
**(b) OF THE PATENTS ORDINANCE 2000**

In the matter of Patent No. **142217** of **15/9/2009** Priority date **23/09/2008** (Europe). Accepted in the name of: - **METHANOL CASALE SA.**, of Via Giulio Pocobelli, 6, CH-6900 Lugano-Besso, Switzerland.

In pursuance of an application received on 28/12/2015.

The following entry has been made in the Register of Patents:-

**CASALE SA**, of Via Pocobelli 6, CH-6900 Lugano, Switzerland, as proprietor by virtue of Merger of **METHANOL CASALE SA.**, into **CASALE SA**, according to the merger agreement dated 24<sup>th</sup> April, 2014.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) SECTION 37**  
**(b) OF THE PATENTS ORDINANCE 2000**

In the matter of Patent No. **142215** of **29/6/2009** Priority date **04/7/2008** (Europe). Accepted in the name of: - **AMMONIA CASALE S.A.**, Via Giulio Pocobelli, 6, CH-6900 Lugano-Besso, Switzerland.

In pursuance of an application received on 28/12/2015.

The following entry has been made in the Register of Patents:-

**CASALE SA**, of Via Pocobelli 6, CH-6900 Lugano, Switzerland, as proprietor by virtue of Merger of **AMMONIA CASALE S.A.**, into **CASALE SA**, according to the merger agreement dated 24<sup>th</sup> April, 2014.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) SECTION 37**  
**(b) OF THE PATENTS ORDINANCE 2000**

In the matter of Patent No. **142146** of **5/10/2009** Priority date **16/10/2008** (Europe). Accepted in the name of: - **UREA CASALE S.A.**, A Swiss company, of Via Giulio Pocobelli, 6, CH-6900 Lugano-Besso, Switzerland.

In pursuance of an application received on 13/10/2015.

The following entry has been made in the Register of Patents:-

**CASALE SA**, of Via Pocobelli 6, CH-6900 Lugano, Switzerland, as proprietor by virtue of Merger of **UREA CASALE S.A.**, into **CASALE SA**, according to the merger agreement dated 24<sup>th</sup> April, 2014.



**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) SECTION 37**  
**(b) OF THE PATENTS ORDINANCE 2000**

In the matter of Patent No. **142155** of **2/11/2007** Priority date **4/11/2006** (Europe). Accepted in the name of: - **UREA CASALE S.A.**, A Swiss company, of Via Giulio Pocobelli, 6, CH-6900 Lugano-Besso, Switzerland.

In pursuance of an application received on 13/10/2015.

The following entry has been made in the Register of Patents:-

**CASALE SA**, of Via Pocobelli 6, CH-6900 Lugano, Switzerland, as proprietor by virtue of Merger of **UREA CASALE S.A.**, into **CASALE SA**, according to the merger agreement dated 24<sup>th</sup> April, 2014.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) SECTION 37**  
**(b) OF THE PATENTS ORDINANCE 2000**

In the matter of Patent No. **142080** of **21/12/2009** Priority date **22/12/2008** (USA). Granted to: -  
**Cubist Pharmaceuticals, Inc., of 65 Hayden Avenue Lexington, Massachusetts 02421, United States of America, United States of America.**

In pursuance of an application received on 19/01/2016.

The following entry has been made in the Register of Patents:-

**MERCK SHARP & DHOME CORP.**, a corporation organized and existing under the laws of the State of New Jersey, United States of America, of 126 East Lincoln Avenue Rahway, New Jersey 07065, United States of America, as proprietor by virtue of Deed of Assignment dated 10<sup>th</sup> June, 2015 made between **Cubist Pharmaceuticals, Inc**, as Assignor of the One Part and **MERCK SHARP & DHOME CORP**, as assignee of the Other Part.

## **NOTIFICATION**

### **PROCEEDING UNDER SECTION 42 OF PATENT ORDINANCE, 2000**

Any person may give notice of opposition to the amendment proposed in the under mentioned patent No. 142080 dated 21/12/2009 (Priority Date: 22/12/2008), lodging Form 7 of the Patent Rules, 2003 together with the prescribed fee of Rs. 1500/- at any time within two months from the date of advertisement in the Gazette, at the Patent Office, 2<sup>nd</sup> Floor Kandawala Building, M.A. Jinnah Road, Karachi.

**Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, Massachusetts 02421, United States of America.**

SEEK TO AMEND THE Specification Page 86-88 of the Claims as above for the invention entitled:

**“A compound N-{1-[(E)-3-(4-pentylphenyl)but-2-enoyl]-L-tryptophyl-D-asparaginy-L-a-aspartyl-L-threonylglycyl-L-ornithyl-L-a-aspartyl-D-alanyl-L-a-aspartylglycyl-D-seryl-(3R)-3-methyl-L-a-glutamyl-(aS)-a,2-diamino- $\gamma$ -oxobenzenebutanoic acid (13-4)-lactone and composition comprising thereof”.**

The proposed amendment is desired by way of correction.

The proposed amendment may be inspected in the Patent Office.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) SECTION 37  
(b) OF THE PATENTS ORDINANCE 2000**

In the matter of Patent No. 141623 of 5/10/2005 Priority date 7/10/2004 (USA). Granted to: - **Wyeth, and** later on whose name was changed to **Wyeth LLC**, and than assigned to **Zoetis W LLC**

In pursuance of an application received on 27/7/2015.

The following entry has been made in the Register of Patents:-

**ZOETIS SERVICES LLC**, of 100 Campus Drive, Florham Park, NJ 07932, United States of America, as proprietor by virtue of merger of **Zoetis W LLC** and merged into **ZOETIS SERVICES LLC** according to the merger certificate dated: 26<sup>th</sup> April, 2015.

**PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE  
OF NAME IN THE REGISTER OF PATENTS.**

*In the matter of Patent No. 136678, dated: 07/01/1999. Granted to: - Bristol-Myers Squibb Co., corporation of Delaware having its office at Lawrenceville-Princeton Road, Princeton, New Jersey, United States of America.*

*And later on assigned to: **Bristol-Myers Squibb Holdings Ireland, of Neuhofstrasse 6, 6340 Baar, Switzerland.***

*In pursuance of an application received on 2<sup>nd</sup> February, 2015.*

*The following entry has been made in the Register of Patents. The Business Address of patentee has been changed to: **“Hinterbergstrasse 16, 63121 Steinhausen, Switzerland”.***

**PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE  
OF NAME IN THE REGISTER OF PATENTS.**

In the matter of Patent No. 137477 dated 18-10-2000 (Priority date 20-10-1999 (Japan).  
Granted to: - ALTANA Pharma AG, (a German company) of Byk Gulden-Str. 2, DE- 78467  
Konstanz, Germany. And later on whose name was changed to: **Nycomed GmbH.**

In pursuance of an application received on 22/7/2013

The following entry has been made in the Register of Patents:-

The Address of the patentee has been changed to: **Takeda GmbH.**

**PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE  
OF NAME IN THE REGISTER OF PATENTS.**

In the matter of Patent No. 141356 dated 14/6/2010, Priority Date: 23/06/2006 (Europe) Granted to: - **Tibotec Pharmaceuticals Ltd, of Eastgate Village Eastgate, Little Island Co Cork Ireland.**

In pursuance of an application received on 30/03/2016.

The following entry has been made in the Register of Patents:-

The Name of the patentee has been changed to:-“**Tibotec Pharmaceuticals**”

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55 OF THE  
PATENTS ORDINANCE 2000**

In the matter of Patent No. **141356** of **14/6/2010** (Priority date **23/6/2006 Europe**), **Granted to:- Tibotec Pharmaceuticals Ltd**, of Eastgate Village Eastgate, Little Island Co Cork Ireland. And later on company name was changed to **Tibotec Pharmaceuticals** and again company name was changed to **Janssen R&D Ireland**.

In pursuance of an application received on **30/03/2016**.

The following entry has been made in the Register of Patents:-

**Janssen Sciences Ireland UC**, a private unlimited liability company incorporated under the law of Ireland with registered number **285805** of Eastgate Village Eastgate Little Island Co Cork Ireland (“**JRD**”), as proprietor by virtue of Deed of Assignment dated **13<sup>th</sup> August, 2015** made between, **Janssen R&D Ireland.**, as Assignor of the one part and, **Janssen Sciences Ireland UC**, as Assignee of the other parts.



**PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE  
OF NAME IN THE REGISTER OF PATENTS.**

In the matter of Patent No. 141356 dated 14/6/2010, Priority Date: 23/06/2006 (Europe) Granted to: - **Tibotec Pharmaceuticals Ltd, of Eastgate Village Eastgate, Little Island Co Cork Ireland. And later on company name was changed to: “Tibotec Pharmaceuticals”**

In pursuance of an application received on 30/03/2016.

The following entry has been made in the Register of Patents:-

The Name of the patentee has been changed to:-**“Janssen R&D Ireland”**

**PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE  
OF NAME IN THE REGISTER OF PATENTS.**

In the matter of Patent No. 141347 dated 21/06/2007, Priority Date: 23/06/2006 (Europe) Granted to: - **Tibotec Pharmaceuticals Ltd, of Eastgate Village Eastgate, Little Island Co Cork Ireland. And later on company name was changed to: “Tibotec Pharmaceuticals”**

In pursuance of an application received on 30/03/2016.

The following entry has been made in the Register of Patents:-

The Name of the patentee has been changed to:-**“Janssen R&D Ireland”**

**PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE  
OF NAME IN THE REGISTER OF PATENTS.**

In the matter of Patent No. 141347 dated 21/06/2007, Priority Date: 23/06/2006 (Europe) Granted to: - **Tibotec Pharmaceuticals Ltd, of Eastgate Village Eastgate, Little Island Co Cork Ireland.**

In pursuance of an application received on 30/03/2016.

The following entry has been made in the Register of Patents:-

The Name of the patentee has been changed to:-**“Tibotec Pharmaceuticals”**

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55 OF THE  
PATENTS ORDINANCE 2000**

In the matter of Patent No. **141347** of **21/06/2007** (Priority date **23/06/2006 Europe**), **Granted to:- Tibotec Pharmaceuticals Ltd**, of Eastgate Village Eastgate, Little Island Co Cork Ireland. And later on company name was changed to **Tibotec Pharmaceuticals** and again company name was changed to **Janssen R&D Ireland**.

In pursuance of an application received on **30/03/2016**.

The following entry has been made in the Register of Patents:-

**Janssen Sciences Ireland UC**, a private unlimited liability company incorporated under the law of Ireland with registered number **285805** of Eastgate Village Eastgate Little Island Co Cork Ireland (“**JRD**”), as proprietor by virtue of Deed of Assignment dated **13<sup>th</sup> August, 2015** made between, **Janssen R&D Ireland.**, as Assignor of the one part and, **Janssen Sciences Ireland UC**, as Assignee of the other parts.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55 OF THE  
PATENTS ORDINANCE 2000.**

In the matter of Patent No. **141964** of **6/12/2010** Priority date **11/12/2009 (Europe)**. Granted to:  
- **Janssen R&D Ireland**, an Irish company, of Eastgate Village, Eastgate, Little Island, Co Cork, Ireland, and **Medivir AB**, of P.O. Box 1086, SE-141 22 Huddinge, Sweden.

In pursuance of an application received on 18/09/2015.

The following entry has been made in the Register of Patents:-

**JANSSEN SCIENCES IRELAND UC**, a Private unlimited liability company incorporated under the laws of Ireland with registered No. 472372 and having its registered office at Eastgate Village, Eastgate, Little Island, County Cork, Ireland, as proprietor by virtue of Deed of Assignment dated 13<sup>th</sup> August, 2015 made between **JANSSEN R&D IRELAND**, as Assignor of the One Part and **JANSSEN SCIENCES IRELAND UC**, as assignee of the Other Part.

**PROCEEDING UNDER SECTION 45 OF THE ORDINANCE 2000.**

Notice is hereby given that an application under section 45 of the Patents Ordinance, 2000 for restoration of a lapsed Patent No. 141332, dated: 03/4/2008, for the invention entitled “**A METHOD FOR THE DETERMINATION OF MICROALBUMINURIA AND SYSTEM FOR CONDUCTING SUCH A METHOD THEREOF**”

Which ceased on 03/04/2014 has been left at the Patent Office 29/6/2016 on behalf of the Patentee, **Dr. Farkhanda Gafoor** (a Pakistani citizen), of National Health Research Complex (NHRC), Pakistan Medical Research Council (PMRC), Shaikh Zayed Medical Complex (SZMC), Lahore.

Any person may give notice of opposition to the restoration by lodging form P-7 of the Patent Rules 2003, accompanied by the prescribed fee of Rs. 1500/- of the Patent Office, 2<sup>nd</sup> Floor Kandawala Building, M.A. Jinnah Road, Karachi within two months from the date of advertisement in the Gazette.

Will appear in the Gazette. \_\_\_\_\_ 2016.

---

**NEW APPLICATIONS FOR THE INDUSTRIAL DESIGNS**

<b>S. No.</b>	<b>Design No.</b>	<b>Title &amp; Class</b>	<b>Applicant</b>
<b><u>12/07 /2016</u></b>			
1	18308	Plastic Box (Class-03)	Mark Industries
<b><u>13/07 /2016</u></b>			
2	18309	Football (Class-06)	Silver Star Ent. Pvt. Ltd.
3	18310	Football (Class-06)	Silver Star Ent. Pvt.
<b><u>14/07 /2016</u></b>			
4	18311	Plastic Basket (Class-03)	Decent Plastic
5	18312	Plastic Basket (Class-03)	Decent Plastic
6	18313	Plastic Basket (Class-03)	Decent Plastic
7	18314	Plastic Basket (Class-03)	Decent Plastic
<b><u>15/07 /2016</u></b>			
8	18315	Bottles (Class-12)	M/s. Unipet (Pvt) Ltd.
9	18316	Bottles (Class12)	M/s. Unipet (Pvt) Ltd.

## REGISTRATION OF DESIGNS

The following designs have been registered.

<b>S. No.</b>	<b>Design No.</b>	<b>Title &amp; Class</b>	<b>Applicant</b>
<b><u>11/07 /2016</u></b>			
1	17191	Cement Bag (Class-03)	M/s. Maple Leaf Cement Factory Limited
2	17192	Cement Bag (Class-03)	M/s. Maple Leaf Cement Factory Limited
3	17321	Laundry Basket (Class-03)	M/s. Rolex Plastic Industries
4	17442	Motor Cycle Indicator (Class-03)	Sara Automobile Industries
5	17535	Chappal (Class-10)	Summit Footwear Co., Ltd
6	17542	Chappal (Class-10)	Summit Footwear Co., Ltd
7	17675	Automobile (Class-01)	Honda Motor Co., Ltd
8	17690	Biscuit (Class-12)	Ismail Industries Limited
9	17722	Remote Control (Class-03)	Dante Ramel Olivar
10	17827	UV Water Purifier With Hot Attachment (Class-12)	Unilever PLC
11	17828	Water Purifier With Ozone (Class12)	Unilever PLC
12	17829	Water Purifier With Fortification Unit (Class-12)	Unilever PLC
13	17841	Security Seal Cap (Class-03)	HSIL Limited
14	17857	Cutlery Set (Class-01)	Azad Cutlery Work
15	17858	Cutlery Set (Class-01)	Azad Cutlery Work
16	17859	Serving Spoon Set (Class-01)	Azad Cutlery Work



17	17872	Sharpener (Class-03)	M/s. National Cottage Industries
18	17936	Plate (Class-03)	Dove Melaminne Ware
19	18037	Music Harp (Class-12)	M/s. Halifax & Co. (Pvt) Limited



**Dr. Mohammad Fayyaz Ahmad**  
Controller of Patents  
& Registrar of Designs  
Ph: 99215488